XTalks

FEBRUARY 14, 2024

This includes first-in-class immunotherapy products such as novel antibodies and CAR T-cell treatments targeting CTLA-4. OncoImmune was founded in 2000 based on the scientific discoveries of the company’s founders who moved their lead product from a basic concept into clinical trials for multiple indications.

Life Science 119

Life Science DNA Production Clinical Trials 119

Pharmaceutical Technology

MARCH 1, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The drug candidate targets DNA-dependent protein kinase (DNA-PK). The drug candidate is administered through the oral route in the form of capsule and tablet. It is a new chemical entity.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. The drug candidate targets DNA-dependent protein kinase (DNA-PK). The drug candidate is administered through the oral route in the form of capsule and tablet. It is a new chemical entity.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Drug Discovery World

JUNE 7, 2023

Hosted by DDW and sponsored by DNA Script, join us for this free-to-attend roundtable to learn about the biggest opportunities for the future of drug discovery and development. Is it true that the next era will belong to antibody drug conjugates? What changes can we expect from clinical trials?

Development 52

Development Gene Therapy Drugs DNA 52

Drug Discovery World

JUNE 27, 2023

Hosted by DDW and supported by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Is it true that the next era will belong to antibody drug conjugates? What changes can we expect from clinical trials? will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET.

Drugs 52

Drugs Gene Therapy DNA Antibody 52

Drug Discovery World

JUNE 22, 2023

Hosted by DDW and supported by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Is it true that the next era will belong to antibody drug conjugates? What changes can we expect from clinical trials? will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET.

Drugs 52

Drugs Gene Therapy DNA Antibody 52

Drug Discovery World

JUNE 15, 2023

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Is it true that the next era will belong to antibody drug conjugates? What changes can we expect from clinical trials? will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET.

Development 52

Development Drugs Gene Therapy DNA 52

Drug Discovery World

JUNE 8, 2023

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Is it true that the next era will belong to antibody drug conjugates? What changes can we expect from clinical trials? will be free to attend on June 28 at 8AM PT | 11AM ET | 4PM BST | 5PM CET.

Development 52

Development Drugs Gene Therapy DNA 52

Drug Discovery World

DECEMBER 21, 2023

Other biotechnologies coming to the fore this year were antibody-drug conjugates and CRISPR gene editing. Regulatory issues and diversity in clinical trials were also important in 2023, as well as the role that artificial intelligence tools like ChatGPT might play.

Gene Therapy 59

Gene Therapy Gene Antibody FDA Approval 59

Delveinsight

DECEMBER 1, 2020

BASE10 Collaborates with DNA Link for COVID-19 Antibody Test Research. US-based BASE10 Genetics and Korean firm DNA Link announced a collaboration on a research project to appraise the usability of the DNA Link’s antibody test, AccuFind COVID-19 IgG, in a healthcare setting.

Antibody 52

Antibody DNA Clinical Trials Clinical Trials 52

Drug Discovery World

FEBRUARY 28, 2024

Using a technique they’ve dubbed ‘cancer shredding’, the researchers at Gladstone Institutes, California, programmed CRISPR to zero-in on repeating DNA sequences present only in recurrent tumour cells – and then obliterate those cells by snipping away at them. expressing cancers.

Development 65

Development Research Drugs Antibody 65

Pharmaceutical Technology

MARCH 2, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It is produced using recombinat DNA technology in Chinese Hamster Ovary (CHO) cells. It is formulated as solution and concentrated solution for infusion for intravenous route of administration.

Production 100

Production DNA Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 24, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Amivantamab overview Amivantamab-vmjw (Rybrevant) is a low-fucose human immunoglobulin G1-based bispecific antibody developed using recombinant DNA technology.

Recombinant DNA Technology 100

Recombinant DNA Technology Production Antibody FDA Approval 100

Drug Discovery World

APRIL 8, 2024

Bold Therapeutics’ BOLD-100, a ruthenium-based small molecule, acts by targeting GRP78 to modulate the unfolded protein response (UPR) and by generating reactive oxygen species (ROS) leading to DNA damage and cell cycle arrest. ADC for treating solid tumours’ demonstrated Claudin 18.2-specific

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

XTalks

NOVEMBER 30, 2023

The safety and efficacy of Cabenuva were established through two randomized, open-label, controlled clinical trials involving 1,182 HIV-infected adults who were virologically suppressed (HIV-1 RNA less than 50 copies/mL) before initiating Cabenuva treatment. Additionally, Gag-specific CD8+ T cells demonstrated an increase of 1.7

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

Find Me Cure

OCTOBER 13, 2019

There currently are drugs that do just that but now they’re in clinical trials for metastatic breast cancer as well. There are antibody drugs targetting those cells that are already FDA approved and there are antibody drugs still in trials. In phase II clinical trial, led by Steven A. Rosenberg, M.D.

Development 52

Development DNA Clinical Trials Clinical Trials 52

XTalks

FEBRUARY 13, 2023

Radiopharmaceutical therapy (RPT) uses isotopes that are conjugated to tumor-targeting agents (such as peptides, antibodies and novel small molecules). Radionuclide-ligand conjugates, including radionuclides that are conjugated to antibodies or peptides, have been studied extensively. How does Radiation Cause Cell Death?

Clinical Trials 52

Clinical Trials Clinical Trials Trials DNA 52

pharmaphorum

OCTOBER 26, 2021

Antibody therapies meanwhile have been developed for non-hospitalised patients, but these still have to be administered by infusion in a clinic. Merck says however that its studies indicate that the drug does not affect mammalian DNA. Pfizer’s drug is currently in late-stage clinical trials.

Drugs 105

Drugs DNA Trials Medicine 105

XTalks

SEPTEMBER 2, 2021

The AlzoSure Predict prognostic biomarker Alzheimer’s blood test detects levels of an unfolded conformational variant of the p53 protein in the blood using a proprietary antibody called U-p53AZ. It is known as the “guardian of the genome” given its central role in the DNA damage response. Diadem’s Alzheimer’s Blood Test.

Protein 105

Protein DNA Antibody Genome 105

Drug Discovery World

APRIL 15, 2023

BDC-3042 is an agonistic antibody targeting Dectin-2, an immune-activating receptor expressed by TAMs. In preclinical studies, Surface Oncology has shown that SRF114 induces antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) pathways to deplete intratumoural Treg cells.

Antibody 52

Antibody Trials Research Gene Editing 52

XTalks

NOVEMBER 1, 2022

The most common treatment for the conditions has been tumor necrosis factor (TNF) blocker therapy, in which the TNF antibodies supress the activity of TNF in the body to reduce inflammation. Rinvoq Efficacy, Safety and Tolerability Assessed in SELECT-AXIS 2 Clinical Trial.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials Trials 52

pharmaphorum

FEBRUARY 5, 2021

DNA testing company 23andMe has signed a deal to merge with a ‘blank cheque’ company set up by Virgin billionaire Sir Richard Branson as a shortcut to a public listing. 23andMe – which will be valued at around $3.5 The merger is due to complete in the second quarter, and will give 23andMe a listing on the NYSE with the ticker symbol “ME”.

Genetics 52

Genetics DNA Life Science Clinical Trials 52

Delveinsight

FEBRUARY 18, 2021

Bluebird suspends gene therapy trials after two sickle cell patients develop cancer. Bluebird bio has stopped two clinical trials of its sickle cell disease gene therapy after participants developed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). for individual breast cancer patients.

Gene Therapy 52

Gene Therapy Gene Trials Clinical Trials 52

Delveinsight

AUGUST 6, 2020

Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test. Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. ZyCoV-D is designed to introduce DNA that encodes for a viral protein into human cells.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

The Pharma Data

SEPTEMBER 1, 2020

with whom Roche has a global distribution agreement and had also launched a Rapid Antibody Test in July. If the target antigen is present in sufficient concentrations in the sample, it will bind to specific antibodies and generate a visually detectable signal on the test strip, typically with results ready in 15 minutes.

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

XTalks

APRIL 23, 2021

dMMR occurs when a cell is unable to repair errors made during cellular replication, owing to mutations in DNA mismatch repair genes such as MLH1 or MLH2 , resulting in high-frequency microsatellite instability (H-MSI). The immunotherapy received approval as a monotherapy based on GSK’s Biologics License Application (BLA).

FDA Approval 105

FDA Approval Trials Antibody DNA 105

pharmaphorum

DECEMBER 21, 2020

Their technology is based on synthetic messenger RNA – short for ribose nucleic acid – which is a short transcript of a longer DNA code. The body produces antibodies against the protein, which neutralise the virus in the event of an infection.

Vaccination 97

Vaccination Vaccine Doctors Doctor 97

The Pharma Data

NOVEMBER 29, 2020

Observed CMV-neutralizing antibody responses and tolerability profile are consistent with previous interim results. The interim immunogenicity analysis also included CMV-neutralizing antibody data assessed from 33 individuals, a subset of the 41 included in the efficacy analysis. NEW YORK and VIENNA, Austria, Nov.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

pharmaphorum

OCTOBER 12, 2022

The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells. Whitelab Genomics operates a proprietary AI platform to accelerate the development of DNA and RNA-based therapies, also known as genomic therapies. This is just the beginning; the potential is enormous,” he says.

Genome 104

Genome Genomics Medicine Development 104

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130

Delveinsight

JANUARY 25, 2021

Etoposide works by inhibiting topoisomerase II, leading to double-stranded DNA breaks. In patients who are ineligible to undergo transplantation, Alemtuzumab , a monoclonal antibody to CD52 that destroys mature lymphocytes, can be used. For familial cases, Allogeneic hematopoietic cell transplantation is often recommended as a cure.

Marketing 52

Marketing Drugs DNA Clinical Trials 52

Roots Analysis

NOVEMBER 3, 2023

NAD + is involved in a wide range of cellular processes, including energy metabolism, DNA repair, and gene expression. There are several types of NAMPT inhibitors, including small molecules, peptides, and antibodies. NAMPT inhibitors work by blocking the activity of NAMPT, which in turn reduces the production of NAD +.

Development 40

Development Drugs Trials FDA Approval 40

Pharmaceutical Technology

DECEMBER 21, 2022

The latest development is based on the findings from the multinational, single-arm Phase II LOTIS-2 clinical trial of Zynlonta to treat r/r DLBCL in adults who have received two or more lines of systemic treatment previously. A CD19-directed antibody-drug conjugate, Zynlonta attaches to a CD19-expressing cell.

DNA 130

DNA Clinical Trials Clinical Trials Medicine 130

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. The trial compared tirzepatide to insulin glargine in adults with type 2 diabetes and increased cardiovascular risk. The company recognized worldwide revenue of $148.9

Antibody 52

Antibody Sales Development Production 52

Bioengineer

JULY 23, 2021

MUSC Hollings Cancer Center part of promising clinical trial for aggressive lymphoma. MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma. Original Source.

Trials 52

Trials Antibody Drugs Clinical Trials 52

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

APRIL 11, 2024

Treatment of BRCA2-deficient but not wild-type DLD1 cells with BSM-1516 resulted in cell cycle arrest accompanied by DNA damage signalling and accumulation of chromatin-bound RPA32, a marker of ssDNA. LAE119 is a potent and selective PARP1 inhibitor and PARP1-DNA trapper.

HR 52

HR Antibody In-Vitro DNA 52